Stockscreener 앱 받기
3.74
4.10%
-0.16
시간 외 거래:
3.74
전일 마감가:
$3.90
열려 있는:
$3.85
하루 거래량:
743.24K
Relative Volume:
1.06
시가총액:
$153.33M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-0.8558
EPS:
-4.37
순현금흐름:
$-86.46M
1주 성능:
+3.89%
1개월 성능:
+30.31%
6개월 성능:
-65.69%
1년 성능:
-45.40%
1일 변동 폭
$3.6626
$3.9099
1주일 범위
$3.54
$4.00
52주 변동 폭
$2.10
$14.22
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times
Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance
Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan
Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace
SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Verastem preps an NDA as the stock struggles - BioWorld Online
Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders
Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK
Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan
This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News
Verastem Inc (VSTM) stock: A year of ups and downs - US Post News
Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada
Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Verastem whipsaws after updates for cancer drug combo - MSN
Taking the lead: Verastem Inc (VSTM) - SETE News
Guggenheim’s latest rating for VSTM stock - Knox Daily
Verastem Inc’s results are impressive - US Post News
Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle
Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
Verastem's SWOT analysis: oncology firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
Verastem's SWOT analysis: oncology firm's stock faces pivotal phase - Investing.com
Verastem (NASDAQ:VSTM) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Verastem (LSE:0LOV) with Buy Recommendation - Nasdaq
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of “Buy” by Analysts - Defense World
Verastem CFO sells shares worth $257 to cover tax obligations - Investing.com India
Verastem CFO sells shares worth $257 to cover tax obligations By Investing.com - Investing.com Australia
Financial Analysis: Verastem Inc (VSTM)’s Ratios Unveil Key Insights - The Dwinnex
Does Verona Pharma Plc ADR (NASDAQ: VRNA) Still Look Hot This Week? - Stocks Register
Verona Pharma Plc ADR (VRNA) deserves closer scrutiny - US Post News
Evan/ Fa Jones Sells 5,173 Shares of Veracyte, Inc. (NASDAQ:VCYT) Stock - Defense World
Stock Surge: Viridian Therapeutics Inc (VRDN) Closes at 22.30, Marking a -0.89 Increase/Decrease - The Dwinnex
Are Smart Investors Making the Right Decision? Verastem Inc (VSTM) - SETE News
Victory Capital Management Inc. Makes New $527,000 Investment in Savara Inc (NASDAQ:SVRA) - Defense World
Acadian Asset Management LLC Takes $82,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem CEO sells shares worth $513 to cover tax obligations - Investing.com India
Verastem CEO sells shares worth $513 to cover tax obligations By Investing.com - Investing.com South Africa
Verastem director sells shares worth $365 to meet tax obligations By Investing.com - Investing.com Australia
Verastem director Brian Stuglik sells shares worth $937 By Investing.com - Investing.com South Africa
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):